share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3：募资说明书
美股SEC公告 ·  08/14 12:43
Moomoo AI 已提取核心信息
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the Prospectus with details from their quarterly report filed on the same date. The supplement relates to the resale of up to 4,260,000 shares of common stock by selling securityholders. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with the last reported sales price being $0.35 per share as of August 12, 2024. The Quarterly Report attached to the prospectus supplement includes detailed financial information such as a net loss of $14.3 million for the six months ended June 30, 2024, and a decrease in cash and cash equivalents from $2.578 million to $59,000. The report also details the company's reliance on third-party CROs for clinical trials, the risk of which has been highlighted by recent payment difficulties with their CRO for the ASPIRE trial. The company has incurred significant losses since inception and continues to face substantial doubt about its ability to continue as a going concern without additional financing.
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the Prospectus with details from their quarterly report filed on the same date. The supplement relates to the resale of up to 4,260,000 shares of common stock by selling securityholders. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with the last reported sales price being $0.35 per share as of August 12, 2024. The Quarterly Report attached to the prospectus supplement includes detailed financial information such as a net loss of $14.3 million for the six months ended June 30, 2024, and a decrease in cash and cash equivalents from $2.578 million to $59,000. The report also details the company's reliance on third-party CROs for clinical trials, the risk of which has been highlighted by recent payment difficulties with their CRO for the ASPIRE trial. The company has incurred significant losses since inception and continues to face substantial doubt about its ability to continue as a going concern without additional financing.
Panbela Therapeutics, Inc.在2024年8月13日提交了招股说明书补充，以更新并补充展望中的信息，包括同一日期提交的季度报告中的详细信息。该补充与卖方有关，最多可由卖出安全持有人销售4,260,000股普通股。公司的普通股在OTCQb上参考「PBLA」标的进行报价，截至2024年8月12日，最后报告的销售价格为每股0.35美元。招股说明书补充附带的季度报告包括详细的财务信息，例如2024年6月30日止6个月的净亏损为1430万美元，现金及现金等价物从257.8万美元减少至59,000美元。该报告还详细介绍了公司在临床试验方面依赖第三方CRO公司，其风险由于最近与ASPIRE试验的 CRO 付款困难而被突出显示。公司自成立以来已经遭受了巨大的亏损，并持续面临是否需要额外融资以继续作为持续经营的公司的重大疑虑。
Panbela Therapeutics, Inc.在2024年8月13日提交了招股说明书补充，以更新并补充展望中的信息，包括同一日期提交的季度报告中的详细信息。该补充与卖方有关，最多可由卖出安全持有人销售4,260,000股普通股。公司的普通股在OTCQb上参考「PBLA」标的进行报价，截至2024年8月12日，最后报告的销售价格为每股0.35美元。招股说明书补充附带的季度报告包括详细的财务信息，例如2024年6月30日止6个月的净亏损为1430万美元，现金及现金等价物从257.8万美元减少至59,000美元。该报告还详细介绍了公司在临床试验方面依赖第三方CRO公司，其风险由于最近与ASPIRE试验的 CRO 付款困难而被突出显示。公司自成立以来已经遭受了巨大的亏损，并持续面临是否需要额外融资以继续作为持续经营的公司的重大疑虑。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息